Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

V Theodorou, M Chovet, H Eutamene, H Fargeau, M Dassaud, M Toulouse, C Bihoreau, F J Roman, L Bueno

Background and aims: Sigma ligands display antiserotonic activity against various secretagogues, suggesting antidiarrhoeal properties. In this study, we evaluated: (i) the antidiarrhoeal effect of JO 2871, a high affinity sigma ligand, in three models of toxigenic diarrhoea in mice; and (ii) the site and mechanism of action of this compound.

Methods: Faeces were collected after toxin or vehicle administration in male DBA2 or NMRI mice. Diarrhoea was determined by cumulative stool weight (mg) over a 120 minute period. Diarrhoea was induced by intravenous administration of Salmonella enteriditis lipopolysaccharide (LPS), or oral administration of Escherichia coli heatstable (E colista) or Clostridium difficile toxins. Two sigma ligands, igmesine and JO 2871, were administered either orally or intravenously, 60 and 30 minutes before the toxins, respectively. JO 2871 was also given orally 30 minutes after E coli-sta. In addition, JO 2871 was administered intracerebroventricularly five minutes before LPS and E coli-sta. BMY 14802 (1000 µg/kg orally), a sigma receptor antagonist, or cyclosomatostatin (CSS 1 µg/kg intravenously), a somatostatin antagonist, were given five minutes prior to JO 2871 in LPS, E coli-sta, and C difficile toxin treated mice. Gastric emptying and intestinal transit were evaluated after oral JO 2871 and BMY 14802 and intravenous CSS.

Results: Stool weight measured 120 minutes after administration of the toxins was significantly increased. Oral JO 2871 and igmesine dose dependently inhibited toxigenic diarrhoea in all models. ED50 values obtained using JO 2871 (1–20 µg/kg) were more than 40 times lower than those obtained with igmesine. Oral JO 2871 given after E coli-sta also inhibited diarrhoea in a dose dependent manner (ED50 50 µg/kg). Both sigma ligands were active by the intravenous route on LPS and E coli-sta induced stool weight increases. JO 2871 administered intracerebroventricularly failed to block this effect at any dose tested. Both BMY 14802 and CSS reversed the antidiarrhoeal effect of oral JO 2871. JO 2871, BMY 14802, and CSS did not affect transit parameters.

Conclusions: JO 2871 exerts a potent oral antidiarrhoeal effect, acting peripherally through sigma sites and somatostatin release.
terminus, a binding domain for steroids, and one putative transmembrane region.

Sigma sites are widely distributed in the organism. They have been characterised in the central nervous system, liver, endocrine organs, lymphocytes, and also in the digestive tract. For example, using binding studies, Roman and colleagues provided evidence for the presence of σ receptors in the myenteric plexus of guinea pig small intestine. Moreover, autoradiographic studies revealed a dense distribution of σ sites in the mucosa and the submucosal plexus of guinea pig gastrointestinal tract.

Igmesine, a potent and selective sigma ligand, was used as a probe to demonstrate the effects of sigma receptor activation on modulation of intestinal secretion. Indeed, igmesine can exert a proabsorptive effect on jejunal mucosa in vitro through a neuronal pathway. Similarly, igmesine reverses the vasoactive intestinal polypeptide (VIP) induced increase in short circuit current and inhibits prostaglandin induced intestinal secretion in humans. Recently, we have shown that igmesine displays antidiarrhoeal activity in S enteritidis lipopolysaccharide (LPS), E coli-sta enterotoxin, and C difficile toxin induced diarrhoea in mice. In addition, Turvill and colleagues showed that igmesine inhibited cholera toxin and E coli-sta induced jejunal secretion in rats. However, as stimulated intestinal water secretion can be centrally mediated and igmesine can act centrally to modulate visceral functions, we have evaluated the site of action (central vs peripheral) of JO 2871 (a follow up compound of igmesine) in this study.

Hence the aims of the present study were: (i) to evaluate the potential antidiarrhoeal effect of JO 2871 (E)-3-(1-cyclopropylmethyl-2-azinanyl)-1-(3,4-dichlorophenyl)-1-propene (E)-isomer, HCl salt) compared with igmesine in three models of toxicogenic diarrhoea (S enteritidis LPS, E coli-sta, and C difficile toxins); (ii) to determine its site of action (central vs peripheral); and (iii) to attempt to elucidate its mechanism of action.

METHODS

Binding assays

Cloning

Human σ receptor was cloned from the neuroblastoma cell line SK-N-MC using reverse transcription-polymerase chain reaction (PCR) methods. Specific primers were designed according to the published sequence (Genebank accession number HSU75283). The entire cDNA sequence obtained was sequenced to check for the absence of PCR induced mutation, and was proved to be identical to the published one.

Transfection

Transfections were performed using Fugene 6 reagent (Roche, Meylan, France) according to the manufacturer's protocol. Briefly, COS7 cells were seeded in flasks (75 cm²) at a density of 700 000, and two days before transfection 10 µg DNA were added to Fugene 6 and incubated with the cells for six hours. Cells were harvested for performing the binding assays 24–48 hours following transfection in Tris HCl 50 mM, EDTA 1 mM, pH 7.4.

Binding experiments

Cell membrane suspensions (5 µg protein/tube) were incubated (120 minutes at 37°C) with [′H]-(+)-penitazocine (2.5 nM final concentration; 28 and 58 Ci/mmol; NEN, Paris, France) in a final volume of 500 µl. The buffer used as incubation medium was 50 mM Tris HCl, 1 mM EDTA, pH 7.4. Incubations were performed in borosilicate glass tubes.

Non-specific binding was determined in the presence of haloperidol 1 µM. Increasing concentrations of the compounds (from 0.001 nM to 300 nM) were added to the incubation medium.

Incubation was stopped by washing the membranes on GF/B filters previously soaked in the incubation buffer with 0.5% polyethyleneimine added. Washing was performed with 3×2 ml of the incubation buffer maintained at 4°C.

Filters were transferred to scintillation picovials (Packard Meriden, USA) and added to 5 ml of Emulsifier Scintillator Plus (Packard). Counting of scintillation was performed in a Tri-carb spectrometer (Packard).

Calculations

Inhibitor concentration 50 (IC50) values were determined by non-linear regression from the inhibition values of specific binding using GraphPad Prism software. Ki values were calculated from IC50 values according to Cheng and Prussoff. The Hill slope corresponding to each curve was calculated by the software.

In vivo experimental design

Faecal output measurement

Animals

Male DBA, mice (20–25 g body weight; Janvier, Le Genest St Isle, France) or NMRI mice (30–35 g body weight; Harlan, Gannat, France) were individually housed in propylene cages and kept in a temperature controlled room (21 (1)°C). They were allowed free access to water and fed ad libitum with laboratory pellets (UAR Epinay-sur-Orge, France).

Faeces were collected and weighed every 30 minutes over a 120 minute period after administration of S enteritidis LPS, E coli-sta, or C difficile toxins A and B. Faecal output was determined by measuring cumulative stool weight (mg) over a 120 minute period.

The activity of the pharmacological agents tested was calculated according to the following formula:

\[
\% \text{of activity} = 100 \times \left( \frac{T-P}{T-C} \right)
\]

where T=mean stool weight (mg), collected over 120 minutes after toxin administration; P=mean stool weight under treatment (mg), 120 minutes after toxin administration; C=mean stool weight of control groups (mg), 120 minutes after vehicle administration.

S enteritidis LPS

Twenty eight groups of 10–12 male DBA were used. Diarrhoea was induced by intravenous administration of S enteritidis LPS (15 mg/kg). For oral treatment, JO 2871 (1–100 µg/kg), igmesine (0.1–1 mg/kg), or vehicle (saline 0.2 ml) were administered 60 minutes before induction of diarrhoea. For intravenous pretreatment, JO 2871 (0.3×10 g/kg), igmesine (0.1–1 mg/kg), or saline (0.1 ml) were administered 30 minutes prior to S enteritidis LPS administration. In another series of experiments, JO 2871 (10 g/kg) was also given by the intracerebroventricular route five minutes before S enteritidis LPS. The somatostatin receptor antagonist cyclo (7-aminoheptanoyl-PHE-D-TRP-LYS-THR(BZL)) (cyclo-somatostatin (CSS) 1 µg/kg intravenously) or the sigma receptor antagonist BMY 14802 (1 mg/kg orally) were given to S enteritidis LPS treated mice five minutes prior to JO 2871 (10 g/kg orally). The effect of these two antagonists (CSS, BMY 14802) alone was also evaluated in two distinct groups of mice.

E coli-sta

Twenty five groups of 10–12 male NMRI mice were used. Diarrhoea was induced by oral administration of E coli-sta (70 µg/kg). JO 2871 (10–1000 µg/kg), igmesine (0.5–1 mg/kg), or saline (0.2 ml) were administered orally 60 minutes prior to induction of diarrhoea. JO 2871 or saline was also injected intracerebroventricularly (5 µl at doses from 0.1×10 g/kg) or intravenously (0.1 ml at doses of 0.1–100 µg/kg) five
and 30 minutes, respectively, before gavage with the E coli-sta solution. Igmesine was also given intravenously (500–3000 µg/kg) 30 minutes prior to E coli-sta administration. In two other groups, CSS (1 µg/kg intravenously) and BMY 14802 (1000 µg/kg orally) were given five minutes before JO 2871 (50 µg/kg orally) or saline in E coli-sta treated mice.

**Preventive versus curative effect**

In a separate series of experiments, five groups of 10–12 male NMRI mice were used. JO 2871 (1–1000 µg/kg) or saline (0.2 ml) was administered orally 30 minutes after oral administration of E coli-sta (70 µg/kg) and faecal output was evaluated over 120 minutes after toxin administration, as previously described.

**C difficile toxins**

Eleven groups of 10–12 male NMRI mice (30–35 g body weight) were used. Diarrhoea was induced by oral administration of a C difficile A and B toxin mixture (5 ng/mice). JO 2871 (0.01–1000 µg/kg), igmesine (500–3000 µg/kg), or saline (0.2 ml) were administered orally 60 minutes before the C difficile toxins. CSS (1 µg/kg intravenously) and BMY (1000 µg/kg orally) were also administered five minutes before JO 2871 (50 µg/kg orally) in C difficile toxin treated animals.

**Transit evaluation**

Four groups of 10–12 male NMRI mice were used. Gastric emptying (GE) and small intestinal transit were assessed according to the technique described by Porreca and Burks. Animals received an oral test meal consisting of 0.5 ml of reconstituted milk (1 g of milk powder in 3 ml of water containing 1 µCi/ml of 51Cr sodium chromate). Thirty minutes later, the animals were sacrificed by cervical dislocation and the stomach and small bowel removed. These organs were placed on a ruled template, and the intestine was cut into 10 segments of equal length. Then the stomach, intestinal segments, and proximal colon were placed into individual test tubes and counted in a gamma radiation counter for two minutes. GE was calculated as a percent of the total counts found in the small intestine and colon. Intestinal transit was evaluated by the described geometric centre (GC) technique according to the following formula:

\[ GC = \Sigma (\text{fraction of counts in each segment}) \times (\text{segment number}) \]

JO 2871 (1000 µg/kg orally) and BMY 14802 (1000 µg/kg orally) were administered 60 minutes prior to the test meal. CCS (1 µg/kg intravenously) was given 30 minutes before the test meal.

**Drugs and chemicals**

*S enteriditis* LPS, E coli-sta, and CSS were purchased from Sigma Chemical Co (St Louis, Missouri, USA). C difficile toxin A and B were provided by Dr G Corthier (INRA Jouy en Josas, France). BMY 14802 was synthesised at Pfizer Global R&D, Fresnes Laboratories.

**Statistical analysis**

Differences in stool weight between toxin treated mice and controls, as well as transit parameters between JO 2871, BMY14802, and CCS treated mice and controls were determined using ANOVA followed by the unpaired *t* test. The criterion for statistical significance was set at *p*<0.05.

**RESULTS**

**Binding**

JO 2871 displayed a Ki value (0.26 (0.10) nM) on cloned human σ1 receptor that was approximately 30-fold higher than that of its corresponding stereoisomer JO 2870 (Ki 6.7 (4.31) nM), 70-fold higher than that of igmesine (Ki 18 (3) nM), and 40-fold higher than that of (+) pentazocine (Ki 8.2 (1.2) nM). The racemate (JO 2514) corresponding to JO 2871 displayed a Ki of 1.36 (0.81) nM (table 1).

All of these compounds dose dependently displaced the specific binding of [3H](+)-pentazocine with total inhibition of specific binding with increasing concentrations. The Hill slope (*n*) was very close to 1 in all cases (table 1), suggesting that the competition curves were following the law of mass action (fig 1).

**Influence of toxins in mice**

All toxins used in this study resulted in emission of watery faeces and an increase in faecal output over the 120 minute period after their administration (fig 2). Stool weight increases compared with controls after *S enteriditis* LPS, E coli-sta, and *C difficile* toxin A and B were 452%, 360%, and 390%, respectively.

**Oral antidiarrhoeal effect of JO 2871 versus igmesine**

Both sigma ligands (JO 2871 and igmesine) given orally reduced 120 minute faecal output in a dose dependent manner in the three models of toxigenic diarrhoea tested. However, JO 2871 exerted its effect at significantly lower doses than igmesine in the three models. Indeed, for *S enteriditis* LPS induced diarrhoea, efficacy dose 50 (ED50) values were 10 and 415 µg/kg for JO 2871 and igmesine, respectively (fig 3). JO 2871 and igmesine also blocked *E coli*-sta induced diarrhoea with ED50 values of 20 and 1603 µg/kg, respectively (fig 3).

**Table 1** Comparative affinities for cloned human σ1 receptor of JO 2871, its stereoisomer JO 2870, and the corresponding racemate JO 2514, with igmesine and pentazocine

<table>
<thead>
<tr>
<th>Compound</th>
<th>Ki (nM)</th>
<th>n/ (SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JO 2871</td>
<td>0.26 (0.10)</td>
<td>1.34 (0.35)</td>
</tr>
<tr>
<td>JO 2870</td>
<td>6.7 (4.3)</td>
<td>0.98 (0.24)</td>
</tr>
<tr>
<td>JO 2514</td>
<td>1.4 (0.8)</td>
<td>1.3 (0.2)</td>
</tr>
<tr>
<td>Igmesine</td>
<td>18 (3)</td>
<td>1.03 (0.05)</td>
</tr>
<tr>
<td>[+]Pentazocine</td>
<td>8.2 (1.2)</td>
<td>0.84 (0.13)</td>
</tr>
</tbody>
</table>

Results are mean (SEM) of three separate determinations.

**Figure 1** Dose dependent displacement curves of specific binding of JO 2871, its stereoisomer JO 2870, and the racemate JO 2514 on cloned human σ1 receptor compared with igmesine and (+)pentazocine. The curves represent displacement of [3H](+)-pentazocine by increasing concentrations of the compounds. Values are means (SEM) of three separate experiments.

www.gutjnl.com
Antidiarrhoeal properties of JO 2871 on toxigenic diarrhoea in mice

Finally, they inhibited *Clostridium difficile* toxin induced diarrhoea in NMRI mice with an ED$_{50}$ of 1 µg/kg for JO 2871 and 1090 µg/kg for igmesine (fig 3).

JO 2871 administered at a maximal dose active on the models of diarrhoea (1000 µg/kg) did not affect basal faecal output (table 2).

**Preventive versus curative effect of JO 2871**

JO 2871 given orally after toxin administration (*E coli*-sta) also reduced faecal output over 120 minutes in a dose dependent manner in this model of toxigenic diarrhoea. The efficacy of JO 2871 was also observed at low doses (fig 4). However, the ED$_{50}$ value in this curative treatment (50 µg/kg) was 2.5-fold higher than the ED$_{50}$ value corresponding to preventive treatment (fig 4).

**Effect of JO 2871, BMY 14802, and CSS on transit**

The effect of JO 2871 on transit parameters (GE and GC) was tested after oral administration of this compound at a maximal dose active on the models of diarrhoea (1000 µg/kg). The same parameters were evaluated after oral BMY 14802 and intravenous CSS administration at the doses used, which significantly antagonised the antidiarrhoeal effect of JO 2871. None of these compounds exhibited any effect on transit parameters (table 3).

**Antagonism of JO 2871 antidiarrhoeal effect**

Administered orally five minutes before JO 2871 (10 µg/kg), BMY 14802 (1 mg/kg orally) reduced (by 66%) the antidiarrhoeal effect of JO 2871 on *Salmonella enteriditis* LPS induced increase in faecal output (fig 4). At the same dose, BMY 14802 orally also reduced (by 70% and 55%) the antidiarrhoeal effect of JO 2871 (50 µg/kg) on *E coli*-sta and *C difficile* toxin induced diarrhoea, respectively (fig 5).

CSS (1 µg/kg) administered intravenously five minutes before JO 2871 (10 µg/kg) reduced (by 62%) the antidiarrhoeal effect of JO 2871 on *Salmonella enteriditis* LPS induced increase in stool weight (fig 4). At the same dose CSS also reduced (by

![Figure 2](http://gut.bmj.com/)  
**Figure 2** Effect of *Salmonella enteriditis* lipopolysaccharide (LPS) (15 mg/kg intravenously (IV)), *Escherichia coli* heat stable toxin (*E coli*-sta 70 µg/kg orally (PO)), and *Clostridium difficile* toxin (5 ng/mice PO) administration on 120 minute total faecal output in mice (mean (SEM), n=10–12). ***Significantly different (p<0.001) from control.

![Figure 3](http://gut.bmj.com/)  
**Figure 3** Comparative efficacy (% of activity) of JO 2871 and igmesine administered orally (PO) on *Salmonella enteriditis* lipopolysaccharide (LPS), *Escherichia coli* heat stable toxin (*E coli*-sta), and *Clostridium difficile* toxin induced diarrhoea. Note the efficacy of JO 2871 administered orally on all toxigenic diarrhoeas tested, at doses 40–1000 times lower than those of igmesine.

![Figure 4](http://gut.bmj.com/)  
**Figure 4** Comparative efficacy (% of activity) of JO 2871 administered orally (PO) before (preventive) and after (curative) *Escherichia coli* heat stable toxin on this toxigenic diarrhoea. Note the efficacy of both oral treatments in this model at low doses. The ED$_{50}$ value of curative treatment was 2.5-fold higher than the ED$_{50}$ value obtained for the preventive treatment.

![Table 2](http://gut.bmj.com/)  
**Table 2** Comparative influence of oral and intravenous administrations of JO 2871 on basal faecal output

<table>
<thead>
<tr>
<th></th>
<th>Vehicle (1000 µg/kg orally)</th>
<th>JO 2871 (10 µg/kg intravenously)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faecal output (mg) 0–120 min</td>
<td>34 (12)</td>
<td>35 (7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>42 (9)</td>
</tr>
</tbody>
</table>

Values correspond to the total amount of faeces collected from 0 to 120 minutes after treatment with JO 2871.
62% and 49%) the antidiarrhoeal effect of JO 2871 (50 µg/kg) on *E coli* and *C difficile* toxin induced diarrhoea, respectively (fig 5).

**Site of action of JO 2871**

Intravenous treatment with JO 2871 dose dependently inhibited *S enteriditis* LPS induced diarrhoea. The per cent reductions were 27%, 38%, and 55% for 0.3, 1, and 3 × 10−5 µg/kg (table 4). In contrast, administered by the intracerebroventricular route, at doses of 0.03–10 µg/kg, JO 2871 did not modify *S enteriditis* LPS induced diarrhoea (table 4). Similarly, JO 2871 given intracerebroventriculatly dose dependently blocked *E coli* induced diarrhoea (table 4) with per cent reductions of 50%, 80%, and 87% for 0.1, 1, and 10 µg/kg, respectively. At the highest dose tested (10 µg/kg), JO 2871 did not affect basal faecal output. When injected intracerebroventricularly at doses of 0.01–10 µg/kg, JO 2871 failed to inhibit the increased faecal output induced by *S enteriditis* LPS or *E coli*-sta (table 4).

**DISCUSSION**

The high affinity sigma ligand JO 2871, a follow up compound of igmesine, dose dependently inhibited toxicogenic diarrhoea. This study shows for the first time that this effect was exerted through a sigma receptor and involved a somatostatin pathway. Interestingly, oral pretreatment with JO 2871 exerted an antidiarrhoeal effect at very low doses with an ED50 value of approximately 1 ng/kg orally in *S enteriditis* -sta and *C difficile* -sta (70 µg/kg). At the highest dose tested (10 µg/kg), JO 2871 failed to inhibit the increased faecal output induced by *S enteriditis* LPS or *E coli*-sta (table 4).

Although the structure of σ receptors is known, the biochemical basis subserving the action of σ receptors remains elusive. However, several lines of evidences have suggested that σ receptors may be related to regulation of intracellular Ca2+ in cardiac myocytes or in rat brain synaptosomes. More recently, the role of σ receptors in regulating intracellular Ca2+ was examined in NG108 cells. In this study, nanomolar concentrations of sigma ligands potentiated the bradykinin induced increase in cytosolic free Ca2+ concentration and this effect was blocked by a 21-mer antisense oligodeoxynucleotide against the cloned σ receptor. This potentiation may be linked to induction of β and β2 cPKC translocation from cytoplasmic to cell membrane.

**Table 3** Effect of oral (JO 2871 and BMY 14802) and intravenous (cyclosomatostatin (CSS)) administration on gastric emptying (GE) and intestinal transit in mice

<table>
<thead>
<tr>
<th></th>
<th>Gastric emptying (GE) (%)</th>
<th>Intestinal transit (GC units)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle (saline 0.2 ml PO)</td>
<td>44.8 (5.1)</td>
<td>6.6 (0.3)</td>
</tr>
<tr>
<td>JO 2871 (1000 µg/kg PO)</td>
<td>45.1 (4.9)</td>
<td>6.4 (0.3)</td>
</tr>
<tr>
<td>BMY 14802 (1000 µg/kg PO)</td>
<td>47.3 (4.4)</td>
<td>5.9 (0.4)</td>
</tr>
<tr>
<td>CSS (1 µg/kg IV)</td>
<td>44.2 (4.8)</td>
<td>6.2 (0.1)</td>
</tr>
</tbody>
</table>

Values for GE and gastric emptying (GE) were determined 60 minutes after oral (PO) JO 2871 and BMY 14802 administration and 30 minutes after CSS intravenous (IV) administration.

**Table 4** Comparative efficacy of JO 2871 on *Escherichia coli* heat stable toxin (E colista) and *Salmonella enteriditis* lipopolysaccharide (LPS) induced diarrhoea according to the route of administration (oral (PO) v intravenous (IV) v intracerebroventricular (ICV))

<table>
<thead>
<tr>
<th></th>
<th>IV</th>
<th>PO</th>
<th>ICV</th>
</tr>
</thead>
<tbody>
<tr>
<td>E colista (70 µg/kg PO)</td>
<td>0.1</td>
<td>20</td>
<td>&gt;10</td>
</tr>
<tr>
<td><em>S enteriditis</em> LPS (15 mg/kg IV)</td>
<td>4×10-4</td>
<td>10</td>
<td>&gt;10</td>
</tr>
</tbody>
</table>

**Figure 5** Antagonism by BMY 14802 and cyclosomatostatin (CSS) of the effect of JO 2871 on faecal output in mice. *Salmonella enteriditis* lipopolysaccharide (LPS), *Escherichia coli* heat stable toxin (E colista), and *Clostridium difficile* toxins increased faecal output in mice. BMY 14802 (1 mg/kg orally) and CSS (1 µg/kg intravenously) were administered five minutes prior to JO 2871 (10 µg/kg orally) in *S enteriditis* LPS (15 mg/kg intravenously) treated mice. BMY 14802 and CSS at the same doses were administered five minutes prior to JO 2871 (50 µg/kg orally) in *E coli*-sta (70 µg/kg) and *C difficile* toxin (5 ng/mice) treated mice. Significantly different (††p<0.01 and †††p<0.001) from toxins.
membrane compartments.\textsuperscript{14} Moreover, (þ)-pentazocine triggers the translocation of \(\sigma\) receptors from the endoplasmic reticulum to the cytoplasmatic membrane where \(\sigma\) receptors could exert a subsequent, powerful, and rapid regulation of neuronal excitability through a heterotrimeric G protein/PLC/PKC cascade. This finding could evidence a yet undescribed mode of rapid recruitment of membrane bound second messenger cascade (involving PLC and PKC) via activation of an intracellular single transmembrane domain receptor (\(\sigma\), receptor). As a functional complement to these studies, recent results\textsuperscript{25} have demonstrated that sigma ligands modulate electrical activity of isolated neurons in primary culture. This result is in agreement with a possible neuronal site for the antisecretory effects of igmesine, as evidenced by its blockade by tetrodotoxin (TTX).\textsuperscript{23} Igmesine binds \(\sigma\) sites in guinea pig brain cells\textsuperscript{25} and in cloned human recombinant brain cells with a Ki value of 10.4 nM. JO 2871 exhibits higher affinity for sigma receptors compared with igmesine with a Ki of 0.26 nM for the cloned receptors. The antidiarrhoeal effect of JO 2871 is antagonised by BMY 14802, a sigma/5-HT\(_1\) receptor antagonist, supporting an action through the sigma receptor. Furthermore, since the dose of BMY 14802 used did not affect transit parameters, we can suggest that sigma receptors are involved in the antisecretory effect of JO 2871. Autoradiographic studies demonstrated the presence of a dense population of \(\sigma\) binding sites in the mucosal and submucosal plexus of guinea pig gastrointestinal tract.\textsuperscript{26} However, no clear relationship between this specific localisation and the functional role of the \(\sigma\) receptors in the digestive tract has yet been evidenced. Previous studies have shown that igmesine peripherally administered stimulates a colonic motor response to feeding but without affecting colonic motility in the fasted state.\textsuperscript{27} Furthermore, such igmesine induced stimulation of postprandial motility accelerates colonic transit in rats.\textsuperscript{28} Also, in the present study we showed that JO 2871 administered orally in mice did not modify stool weight or transit parameters (GE and intestinal transit). Taken together, these observations reinforce that sigma ligands exert an antisecretory effect as acceleration of colonic transit seems to be inconsistent with the antidiarrhoeal effect observed. The antisecretory effect of igmesine has already been demonstrated after systemic administration\textsuperscript{29} even when administered after the secretory agent.\textsuperscript{30} In this study, we first demonstrated that JO 2871 displayed antidiarrhoeal activity when given orally in a preventive and curative way. The preventive effect was reproduced by intravenous but not intracerebroventricular administration, suggesting that JO 2871 exerts its action on intestinal secretion through a peripheral mechanism. This activity may involve the myenteric plexus and/or intrinsic sensory nerves as the antisecretory action of other sigma ligands such as igmesine was demonstrated to be TTX sensitive in vitro\textsuperscript{12} and in vivo.\textsuperscript{31} Enterotoxins bind enterocyte receptors, triggering intracellular events (for example, increase in cyclic nucleotide concentration) leading to water secretion. For example, \(E\) coli\textsuperscript{-sta} binds cell surface receptors and activates two membrane associated cyclic GMP dependent kinases.\textsuperscript{32} This activation initiates a secretory signalling cascade characterised by a rise in intracellular concentrations of cyclic GMP.\textsuperscript{33} The secretory effect of \(C\) difficile toxin A has also been described to be mediated through a specific epithelial cell receptor, which has been characterised subsequently as an \(\alpha\)-galactose and \(N\)-acetylglucosamine containing glycoprotein receptor coupled to a pertussis toxin sensitive G protein.\textsuperscript{34} Despite local binding to enterocytes, the secretory effect of enterotoxins in vivo depends mainly on local innervation.\textsuperscript{35} This neurally mediated secretory reflex may involve three enteric neurones: (i) a sensory neurone, which has dendrites extending from the mucosa and relaying information to an interneurone in the submucosal and myenteric plexus, (ii) an interneurone projecting to a secretomotor efferent and receiving additional enteric and extrinsic neuronal inputs to modulate this reflex. Indeed lidocaine, tetrodotoxin, and hexamethonium block the effects of bacterial enterotoxins such as \(E\) coli\textsuperscript{-sta} and \(S\) typhimurium toxin.\textsuperscript{36} Moreover, the diarrhoeal effect of \(E\) coli\textsuperscript{-sta} also involves sensory innervation and mast cell degranulation,\textsuperscript{37} underlying the fact that immune cells of the lamina propria participate in neuroimmune regulation of enterotoxin secretory effects in the gut. Similarly, capsaicin sensitive sensory afferent neurones and mast cells are involved in the secretory mechanism of \(C\) difficile toxin A.\textsuperscript{38} More recently a neuronal pathway has also been demonstrated to be involved in rotavirus induced intestinal secretion.\textsuperscript{39} Taken together, these findings reinforce the concept of activation of neuroimmune pathways in the effects of enterotoxins, and other secretory pathogens and sigma ligands may act at this level to suppress the secretory effect of pathogens.

Somatostatin, a peptide released by neuroendocrine cells, has inhibitory effects on gastric, pancreatic,\textsuperscript{9} and intestinal secretion of water and electrolytes.\textsuperscript{40} In addition, somatostatin and its analogue octreotide have been shown to be potent antidiarrhoeal agents in refractory diarrhoea.\textsuperscript{41} The main source of circulating immunoreactive somatostatin is the gastrointestinal tract\textsuperscript{42} and projections of somatostatin-immunoreactive neurones are localised predominantly in the submucous plexus with fewer fibres in the myenteric plexus.\textsuperscript{43} Rat colonic epithelium expresses multiple subtypes of somatostatin receptors, and activation of the SST-R2 subtype mediates inhibition of cAMP dependent ion secretion by both somatostatin and octreotide.\textsuperscript{44}

Somatostatin and igmesine have already been shown to exert similar antisecretory effects on interleukin-1\(\beta\) induced colonic hypersecretion in rats and the effect of igmesine is blocked by CSS.\textsuperscript{45} Similarly, the antidiarrhoeal activity of JO 2871 is antagonised by CSS. Moreover, CSS had no effect on transit parameters. Taken together, these results suggest the involvement of a somatostatin pathway in the antisecretory mechanism of action of JO 2871. Consequently, we can hypothesise that JO 2871 acts peripherally on sigma receptors, probably located within the gut on somatostatinergic neurones, triggering release of somatostatin which in turn acts directly or indirectly on receptors located on enterocytes or on secretomotor neurones to alleviate toxin induced intestinal secretion. The hypothesis of a direct and indirect mechanism involved in the action of somatostatin is supported by previous findings showing a parallel reduction in cholera toxin induced net fluid secretion and in VIP release from the small intestine of the cat.\textsuperscript{46} Activation of sigma receptors inhibits acetylcholine release\textsuperscript{47} and favours noradrenaline release,\textsuperscript{48} and such effects may contribute to its antisecretory action. However, the lack of an anti-transit effect of JO 2871 is not in agreement with this possible mechanism of action.

In conclusion, the high affinity sigma ligand JO 2871 is an effective antidiarrhoeal agent against various toxigenic diarrhoeas. It prevents toxigenic diarrhoea but is also effective as a curative agent. Its activity at very low oral doses against a large spectrum of pathogenic diarrhoeas suggest that it acts distally via a common peripheral neuronal pathway. Based on all of these data we can speculate that JO 2871 provides a new basis for the development of potent antidiarrhoeal therapies.

Acknowledgements

This study was supported by grant 94-4219 of the Direction Générale de la Recherche Scientifique et Technique (France), and by grant 94/3491 of the Ministère de l’Agriculture de Purpan, 75 voie du Toec, 31076 Toulouse, France.

Authors’ affiliations

V Theodorou, H Eutamene, M Toulouse, Ecole Superieure d’Agriculture de Purpan, 75 voie du Toec, 31076 Toulouse, France

M Chovet, H Fargeau, M Dassaud, C Bihoreau, F J Roman, Pfizer Global R&D Fresnes Laboratories, 3–9 rue de la Loge, BP100, 94265 Fresnes, France

L Bueno, Department of Neurogastroenterology and Nutrition, INRA, 180 chemin de Tournefeuille, BP3, 31931 Toulouse, France

References

www.gutjnl.com

Downloaded from http://gut.bmj.com/ on June 22, 2017 - Published by group.bmj.com
REFERENCES


33. Cheng Y, Prussoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% decrease in the reaction (IC50) of an enzymatic reaction. *Biochem Pharmacol* 1973;22:3099–108.


Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

V Theodorou, M Chovet, H Eutamene, H Fargeau, M Dassaud, M Toulouse, C Bihoreau, F J Roman and L Bueno

Gut 2002 51: 522-528
doi: 10.1136/gut.51.4.522